In Brief: Bristol-Myers Squibb's Ovcon 35 withdrawal
Executive Summary
Bristol-Myers Squibb's Ovcon 35 withdrawal: One lot of norethindrone and ethinyl estradiol oral contraceptive tablets voluntarily withdrawn by the company in recall announced Jan. 17. The lot recall involves about 150,000 compacts of blister packs of which a few compacts had weeks one and four (active ingredient vs. placebo) of the therapy transposed...